Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPN-019 for Viral Load Reduction in Early COVID-19
NCT05035576Phase 1Terminated
- Sponsor
- OptiNose
- Start
- Sep 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of OPN-019 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by OptiNose. Primary endpoint: Change in nasal viral load over multiple time points at 24 hours. Started Sep 2021; status: terminated.
02
Drugs
OPN-019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05035576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05035576.